C. Lund

The Distribution and Patterns of Practice of Stereotactic Ablative Body Radiotherapy in Canada.

R. Halperin, Mitchell C C Liu, R. Olson, 2014, Journal of medical imaging and radiation sciences.

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

A. Mestrovic, N. Chng, S. Tyldesley, 2018, BMC Cancer.

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.

A. Mestrovic, N. Chng, S. Tyldesley, 2022, JAMA oncology.

Survival in small cell lung carcinoma after surgery.

P. Alstrup, C. Lund, H. Sørensen, 1986, Thorax.

The Impact of Peer Review of Volume Delineation in Stereotactic Body Radiation Therapy Planning for Primary Lung Cancer: A Multicenter Quality Assurance Study

Jeffrey Cao, Robert Olson, Eric Berthelet, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.

M. McLay, J. Hamm, R. Olson, 2019, Current oncology.

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial.

A. Mestrovic, N. Chng, S. Tyldesley, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

A. Mestrovic, N. Chng, S. Tyldesley, 2018, BMC Cancer.

Progression-free survival and local control following stereotactic ablative radiotherapy for up to 5 oligometastases: an analysis from the population-based phase II SABR-5 trial.

N. Chng, S. Tyldesley, Mengxing Liu, 2022, International journal of radiation oncology, biology, physics.

A perspective on in person scientific meetings

J. Rose, S. Lefresne, C. Mariano, 2023, Radiotherapy and Oncology.